Provide feedbackProvide feedback

Home :: Psychiatry :: ADHD

Euthymics Bioscience starts early-stage adult ADHD trial

Thursday, March 22 2012 | Comments
Evidence Grade 0 What's This?

Euthymics Bioscience Inc. launched a Phase I trial to investigate EB-1020, a next-generation drug intended for the treatment of adult attention-deficit/hyperactivity disorder (ADHD). The trial includes healthy volunteers who have already begun receiving treatment. Final study findings are expected to be available in the third quarter. Peer-reviewed preclinical data have demonstrated that EB-1020, which has a low risk of drug abuse liability, affects areas of the brain that are...

Euthymics Bioscience Inc. launched a Phase I trial to investigate EB-1020, a next-generation drug intended for the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

The trial includes healthy volunteers who have already begun receiving treatment. Final study findings are expected to be available in the third quarter.

Peer-reviewed preclinical data have demonstrated that EB-1020, which has a low risk of drug abuse liability, affects areas of the brain that are associated with ADHD, according to Euthymics.

Latest News

Shire to compare Vyvanse, Concerta in two Phase IV trials Verusmed

Tuesday, March 06 2012 | Comments
Evidence Grade 0 What's This?

Shire Plc is commencing two Phase IV clinical studies to compare its Vyvanse (lisdexamfetamine dimesylate) capsules to Janssen Pharmaceuticals Inc.'s Concerta (methylphenidate hydrochloride) extended-release tablets. Both drugs are used to treat attention-deficit/hyperactivity disorder (ADHD).

The prospectively designed, randomized, double-blind,...

Tags: ADHD, ADHD


Shire's Vyvanse approved for maintenance treatment in adults with ADHD Verusmed

Tuesday, February 07 2012 | Comments
Evidence Grade 0 What's This?

Shire Plc's Vyvanse (lisdexamfetamine dimesylate) capsules received Food and Drug Administration approval as a maintenance treatment for adults with attention-deficit/hyperactivity disorder (ADHD).

The approval was supported by findings from a randomized, Phase IV withdrawal study in which investigators evaluated the efficacy of Vyvanse in 123 adults aged 18 to 55 years who...

Tags: ADHD


Actavis launches first generic version of Novartis' Ritalin LA Verusmed

Wednesday, January 04 2012 | Comments
Evidence Grade 0 What's This?

Actavis Group launched its methylphenidate hydrochloride extended-release capsules, which are the first generic equivalents of Novartis AG's Ritalin LA.

The Food and Drug Administration approved Actavis' generic version of the drug, which is indicated for the treatment of attention-deficit/hyperactivity disorder, last month; it is...

Tags: ADHD, ADHD


Stimulants reduce later risk for developing substance use disorders, smoking in girls with ADHD Verusmed

Wednesday, October 22 2008 | Comments
Evidence Grade 3 What's This?

Prior prescription stimulant therapy appears to protect adolescent girls who have attention-deficit/hyperactivity disorder (ADHD) from the subsequent risk of smoking or having substance use disorders (SUDs), according to a new study.

The prospective, case-control analysis focused on 5-year follow-up interviews with 114 girls with ADHD (average age at follow-up, 16.2 years) who were part of a longitudinal study and had complete medication and SUD data. Structured interviews were...

Tags: ADHD, ADHD




Psychiatry Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos